Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
For the first time, researchers are assessing a pairing of a long-acting antiretroviral and a long-acting antibody.
The trial will investigate whether injections of long-acting cabotegravir and rilpivirine yield a superior rate of viral suppression.
Researchers identified this advancing risk after controlling for expected cognitive decline based on age.
Maxwell contracted polio in 1950 and HIV in 1994. She was a graphic designer and photographer as well as a leader in AIDS clinical trials.
An update from the AIDS Clinical Trials Network.
Advocates urge African Americans to participate in HIV clinical trials.
How pharmaceutical and biotech companies are playing a major role in the search for an HIV cure.
People taking abacavir (found in Ziagen, Epzicom and Trizivir) had no greater risk of having a heart attack than people not taking abacavir, a...
There is a 40 percent higher risk of virologic failure among blacks, compared with whites, who are starting HIV treatment for the first time,...
One of the most intriguing compounds to be studied as an antiretroviral (ARV) is mifepristone, a medication sold in the United States as Mifep...
Truvada (tenofovir and emtricitabine) is more likely to lead to bone loss than Epzicom (abacavir and lamivudine); in addition, Norvir (ritonav...
Death rates of children living with HIV have decreased greatly since antiretroviral therapy became widely available in the mid-1990s.
Women living with HIV who’ve gone through menopause do just as well when starting antiretroviral (ARV) therapy for the first time, compared wi...
A monitoring board for an international trial comparing three antiretroviral (ARV) regimens has found that Reyataz (atazanavir) combined with...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.